Pflug Koory LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Pflug Koory LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,018 shares of the pharmaceutical company’s stock after purchasing an additional 79 shares during the quarter. Pflug Koory LLC’s holdings in Vertex Pharmaceuticals were worth $813,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Goelzer Investment Management Inc. increased its position in Vertex Pharmaceuticals by 1.5% during the fourth quarter. Goelzer Investment Management Inc. now owns 1,915 shares of the pharmaceutical company’s stock worth $771,000 after buying an additional 29 shares in the last quarter. Brighton Jones LLC increased its position in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares in the last quarter. Montecito Bank & Trust raised its stake in Vertex Pharmaceuticals by 2.5% in the 4th quarter. Montecito Bank & Trust now owns 1,659 shares of the pharmaceutical company’s stock valued at $668,000 after purchasing an additional 40 shares during the last quarter. Veracity Capital LLC lifted its holdings in Vertex Pharmaceuticals by 24.8% in the 4th quarter. Veracity Capital LLC now owns 2,019 shares of the pharmaceutical company’s stock valued at $813,000 after purchasing an additional 401 shares in the last quarter. Finally, Avior Wealth Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 17.2% during the fourth quarter. Avior Wealth Management LLC now owns 2,969 shares of the pharmaceutical company’s stock worth $1,196,000 after buying an additional 436 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Down 0.0 %

Vertex Pharmaceuticals stock opened at $439.62 on Friday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $435.88 and its 200 day moving average price is $464.95. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the previous year, the firm posted $3.67 earnings per share. The company’s revenue was up 11.6% compared to the same quarter last year. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the topic of a number of analyst reports. Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Stifel Nicolaus raised their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. HC Wainwright reduced their target price on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a research report on Friday, December 20th. JPMorgan Chase & Co. lowered their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $494.84.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.